The Lambert-Eaton LEMS Family Association

Global Access to Amifampridine for LEMS

Information reviewed August 2026

Purpose

This document identifies countries or regions where FIRDAPSE / amifampridine approval or current market availability has been verified from authoritative sources.



Verified approval / current market listing

- United States[1]
- Canada[2]
- European Union[3]
- United Kingdom[4]
- Japan[5]

Interpretation

An unmarked country should not be interpreted as proof that amifampridine is unavailable. Access may differ through national approvals, local products, clinical programs, hospital supply, or special-access pathways that have not yet been verified for this document.

References

1. U.S. FDA. FIRDAPSE (amifampridine) Prescribing Information, NDA 208078; current label.
2. Health Canada Drug Product Database. FIRDAPSE, DIN 02502984; status: Marketed; product monograph dated June 10, 2025.
3. European Medicines Agency. Firdapse (amifampridine), EPAR; EU marketing authorisation for symptomatic treatment of adult LEMS.
4. electronic Medicines Compendium (UK). FIRDAPSE 10 mg tablets, Summary of Product Characteristics; updated March 24, 2026.
5. DyDo Pharma, Inc. FIRDAPSE Tablets 10 mg (amifampridine phosphate): Japanese approval Sept. 24, 2024; sales launched Jan. 21, 2025.